ABIGAIL CONNOR: Open Payments
NPI 1265202071 · CINCINNATI, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,379 in 138 payments from 25 companies in 2025. Trend: 2023 $17 · 2024 $2,574 · 2025 $3,379
Food & beverage: $3,126Education: $132Consulting: $121
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 21 | $730 |
| GlaxoSmithKline, LLC. | 31 | $547 |
| GENZYME CORPORATION | 19 | $445 |
| Amgen Inc. | 18 | $376 |
| Grifols USA, LLC | 8 | $248 |
| ADMA BioManufacturing LLC | 1 | $121 |
| SANOFI-AVENTIS U.S. LLC | 1 | $98 |
| BioCryst US Sales Co., LLC | 4 | $95 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $74 |
| CSL Behring | 3 | $70 |
Products named: DUPIXENT, NUCALA, TEZSPIRE, FASENRA, AIRSUPRA, Xembify, TRELEGY ELLIPTA, ORLADEYO.
Industry payments across OH — which companies pay providers there.
